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Chapter 4
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Cardiac hypertrophy accompanies many forms of cardiovascular diseases. The mecha-
nisms behind the development and regulation of cardiac hypertrophy in the human 
setting are poorly understood, which can be partially attributed to the lack of human 
cardiomyocyte-based pre-clinical test system recapitulating features of diseased myocar-
dium. The objective of our study is to determine whether human embryonic stem cells 
- derived cardiomyocytes (hESC-CM) subjected to mechanical stretch can be used as an 
adequate in vitro model for studying molecular mechanisms of cardiac hypertrophy. We 
show that hESC-CM subjected to cyclic stretch, which mimics mechanical overload, exhibit 
essential features of a hypertrophic state on structural, functional, and gene expression 
levels. The presented hESC-CM stretch approach provides novel insight into molecular 
mechanisms behind mechanotransduction and cardiac hypertrophy and lays ground 
for the development of new pharmacological approaches as well as for discovering new 
potential circulating biomarkers of cardiac dysfunction.




Heart diseases are among the leading causes of death worldwide1. Cardiac hypertrophy is 
common manifestation of many forms of cardiac disease including heart failure, myocar-
dial infarction and hypertension2.
An important cause of cardiac hypertrophy is mechanical stretch2,3. At the moment when 
this stretch becomes excessive due to the volume or pressure overload, the heart starts 
sending stress signals activating a hypertrophic response program to compensate the 
wall stress. Persistent wall stress leads to a progressive cardiac remodelling and eventually 
the heart goes into a failing state2,3. Understanding the molecular mechanisms underly-
ing development of cardiac hypertrophy is essential for advancing treatments of cardiac 
diseases. However, the absence of adequate research models is a major obstacle to func-
tional studies of molecular mechanisms of cardiac hypertrophy. Human in vitro models 
are limited by the amount of patient-derived primary cells of cardiovascular lineage and 
poor consistency, while existing animal models are not always accurately representing 
the mechanisms responsible for cardiac hypertrophy development due to the significant 
inter-species differences in contractile features, stress response, ion channels expression 
and distribution4-6. Additionally, extensive animal studies are limited by ethical reasons 
and there are strong incentives to limit the use of animal testing in European Union and 
to replace it with alternatives, including the development of technologies such “human-
on-a-chip” via employment of stem cell derived organ specific cells (report on a European 
Commission scientific conference, Cronin, 2017).
Cardiomyocytes (CM) differentiated from human embryonic stem cells (hESC) are a 
powerful tool for investigating cardiac development, function and pathophysiology8,9. 
Subsequently, the availability of human embryonic stem cell-derived CM (hESC-CM) 
provided a relatively cheap platform for drug testing10,11. However, the use of hESC-CM 
for studies of cardiac hypertrophy and downstream molecular effects is not clearly dem-
onstrated12,13. The mechanic force overload, or stretch model, is based on induction of 
mechanical stress by physical stretching of CM. This is a sustained in vitro model that 
mimics volume overload on the heart during cardiac hypertrophy development3,14,15. Ad-
ditional advantage of stretch in vitro model compare to neurohumoral stimulation of 
CM (i.e. phenylephrine stimulation) that it allows to dissect direct effects of increased 
biomechanical load from the secondary neurohumoral activation.
The aim of this study is to determine whether hESC-CM subjected to mechanical stretch 
can be used as an informative in vitro model for investigation of molecular mechanisms 




Cardiac Differentiation of hESC
To differentiate hESC into CM a small molecule-based protocol utilizing modulation of 
Wnt/β-catenin signaling was employed. hESC were treated with 6 µM GSK3-β inhibitor 
CHIR99021 (Cayman Chemicals) for two days, followed by inhibition of WNT signaling 
using 2 μM of Wnt-C59 (Tocris Bioscience). To further increase CM population purity, 
metabolic differences between CM and non-CM were exploit and cells were subjected to 
glucose starvation in presence of 5mM of dl-lactate for 6 days, as was published previ-
ously67.
Application of Mechanical Stretch
CM were cultured on a BioFlex six-well plate (Flexcell international) coated with Geltrex 
(Flex I Culture Plates Collagen I, Flexcell International) and were stretched using an FX-
4000 (Flexcell International). Cyclic equiaxial stretching at a frequency of 1 Hz, mimicking 
humans heart rate (1 Hz = 60 beats per min), and 15% elongation was applied for 48 
hours. Control CM were cultured on identical plates and kept under identical conditions, 
without mechanical stretch application.
Atomic Force Microscopy (AFM)
All beating force and stiffness values were determined by atomic force microscopy (AFM) 
nanoindentation. All measurements were performed with uncoated silicon nitride DNP-10 
cantilever with pyramidal tip (Bruker). According to previously published data this type 
of cantilevers provided most stable force reading results in case of CM biosensing70. 
Cantilevers were first calibrated by the thermal tuning method71. Spring constants were 
always within the range given by the manufacturer (0.053 to 0.077 N/m). AFM measure-
ments were carried out at room temperature in CDM3 media supplemented with 10 mM 
HEPES using a BioScope Catalyst AFM (Bruker) with z-scan rates 1.0 Hz for beating force 
measurements and 3.0 Hz for stiffness measurements, under a maximal loading force of 2 
nN, and indentation depth of 100 nm. Force curves were measured between the cantilever 
and CM and Young’s modulus values were derived using the Sneddon model72,73. We used 
a Poisson’s value of 0.5 for the cell. Indentation module of NanoScope Analysis software 
(Bruker) were used to calculate Young’s modulus (Version 3.0.0.19). CM contractions were 
measured during 60-120 seconds. Typical noise levels during these measurements were 
up to 200 pN. The contraction force and rate were calculated. The contraction force of 
each beat is calculated as a difference between peak value and baseline, the beat rate is 
obtained from the reciprocal of the time interval to the next beat.
Modeling hypertrophy in human cardiomyocytes
75
4
RnA-seq libraries Preparation and Sequencing
RNA-sequencing was performed on 14 HUES9-CM total RNA samples; CM from 7 inde-
pendent differentiations were divided into a control or stretched group. Total RNA was ex-
tracted using Trizol reagent. Quality of extracted RNA were accessed on Bioanalyzer 2100 
(Agilent) using Pico RNA chip (Agilent). All samples passed QualityControl; all exceeded 
a minimum RIN of 8. Then, 1 µg of total RNA from each sample was processed with the 
NEXTflex Poly(A) Beads kit (Bioo Life Science) in order to pull down the mRNA from the 
total RNA samples. Eluted mRNA was further used for library preparation. Libraries were 
generated using NEXTflex™ Illumina qRNA-Seq Library Prep v2 kit (Bioo Life Science). 
At the end of the procedure, libraries were purified with Ampure XP beads (Beckman 
Coulter) and the DNA eluted with 17 μL resuspension buffer. The size and quality of the 
libraries were controlled by running them on a Bioanalyzer 2100 using the High Sensitiv-
ity DNA assay. For sequencing, all 14 samples were pooled and sequenced on Illumina 
HiSeq2500 machine. RNA-seq data were deposited to NCBI Short Read Archive under acc.
no. SRR5875410-SRR5875423.
Gene expression Analysis
PCR duplicate reads were removed using molecular indexes present in RNA-seq librar-
ies made with NEXTflex qRNA-Seq kits. Nonredundant reads were mapped to human 
genome (GRCh38) with STAR v.2.5.2b and gene counts were obtained with STAR’s op-
tion ‘quantMode GeneCounts’ and gene annotations from GENCODE v. 2674,75.Obtained 
gene counts were normalized with RUVSeq using parameter k=5, and differential gene 
expression was calculated with edgeR package76,77.Gene Ontology (GO)-term enrichment 
analysis was performed with GOrilla and visualized with REVIGO78,79. Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway analysis of differentially expressed genes was 
performed with STRING database80.
Statistical Analysis
Values are displayed as medians of at least three independently performed experiments. 
For all graphs: each dot represents results of independent experiments performed on the 
independently derived CM, each dot is a mean of at least two technical replicates. Un-
less stated otherwise statistical comparisons were performed using two-tailed, unpaired 
Student’s t-test (Prism, GraphPad Software). For qRT-PCR, analysis was performed using 
GenEx software (MultiD Analyses AB). The following indications of significance were used 




Generation and Characterization of heSC-CM.
CM were generated from two independent previously characterized hESC lines, HUES9 
and H9, using small molecule-modulated differentiation and subsequent lactate purifica-
tion16,17. Purified CMs were subjected to mechanical stretch (Figure S1A) and examined for 
cardiac hypertrophy-related alterations with several assays (Figure 1A). CM derived from 
both lines expressed standard CM-specific markers (Figure 1B) and exhibited spontane-
ous beating (Movies S1 and S2).
Mechanical Stretch Induces Hypertrophy, ROS Production, Cell Death and Fetal Genes 
Expression in hESC-CM.
Heart cells are exposed to rhythmic contraction or regular cyclic stretch throughout 
adult life. However, chronic biomechanical stress is also an attribute of arterial hyper-
tension or valvular heart disease, eventually leading to cardiac remodeling and cardiac 
hypertrophy development18.
There are several stretch parameters that could influence the hypertrophy response, 
including the duration of stretch and the amount of stretch. Before extensive phenotyping 
was started, we studied several conditions, including different durations of stretch (7, 24, 
and 48 hr) and different amounts of stretch (5% versus 15%). We applied 15% stretch to 
monitor the release of cardiac-specific biomarkers after 7, 24, and 48 hoursof HUES9-CM 
stretch. Interestingly, the most robust release of the N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP), a marker of cardiac stretch, as well as of troponin T (TnT), 
a marker of CM damage, appeared after 48 hours of 15% stretch (Figure S1B). In addi-
tion, mRNA expression level of TnT was not changed during the stretch at different time 
points, but the expression of NTproBNP significantly increased after 7 hours of stretch and 
remained significantly upregulated (Figure S1C). We also looked at two different stretch 
regimes: 5% and 15%. In our setup, application of 5% to HUES9-CMs for 48 hours did not 
induce a clear phenotype. We did not record significant changes in TnT release, increase 
of CM size, or clear induction of stress genes expression (see Figure S2). Therefore, for 
further experiments, 15% cyclic stretch was applied for 48 hr.
Exposure of hESC-CMs to mechanical stretch for 48 hours caused a significant increase 
in cell size in HUES9-CMs (26% ± 9.7%, p < 0.001) (Figures 2A and S3). In order to define 
whether inherited variabilities between hESC lines have an impact on the results, we vali-
dated the model using a different hESC line, H9. Cyclic stretch applied to H9-CM resulted 
in increase of CM size (37% ± 19.6%, p < 0.001), which indicated the robustness of the 
data (Figure 2A).
For both HUES9- and H9-derived CMs we observed a more than 2-fold increase of NT-
pro-BNP and 1.5-fold increase of TnT release after 48 hours of stretch (Figure 2B). After 
48 hours of stretch, a significant increase in reactive oxygen species (ROS) production in 
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HUES9- and H9-derived CMs was observed (Figure 2C). In order to further substantiate 
our claim that cellular hypertrophy is present, we measured CM volume with the use of 
confocal laser scanning microscopy (Zeiss LSM 7MP) on live wheat germ agglutinin (WGA)/
Hoechst stained cells. Confocal imaging was further combined with three-dimensional 
(3D) image processing software (Imaris 6.3.5) to generate a 3D structure of the CMs and 
determine cell volume. We chose not to fi x CM and performed experiments on live cells, 
since fi xation causes shrinkage of the cells in the z-direction. Our results show that appli-
cation of 15% stretch leads to a signifi cant increase in CM volume compared with control 
B




Figure 1 - Study Workfl ow. (A) CMs were subjected to mechanical stress for 48hoursand assessed for 
changes in cell size, gene expression, cell stiff ness, reactive oxygen species (ROS) production, and stress 
marker release. AFM, atomic force microscopy; RNA-seq, RNA sequencing; hESC-dCMs, human embryonic 
stem cell-derived cardiomyocytes; KD, knockdown. ** p < 0.01, *** p < 0.001. (B) Fluorescent microscopy im-
ages of diff erentiated hESC-CMs expressing cardiac-specifi c markers cardiac troponin T (TnT) and a-actinin 









































Exp # Eﬀect size (%) P-value
1 10.5 1.2 x 10-2
2 48.5 9.2 x 10-27
3 54.7 2.2 x 10-35
4 34.4 5.2 x 10-8
5 38.3 1.4 x 10-17
Exp # Eﬀect size (%) P-value
1 14.0 1.1 x 10-8
2 35.6 6.6 x 10-20
3 30.0 2.0 x 10-5
4 33.0 1.1 x 10-16











































































Exp. 1 Exp. 2 Exp. 3 Exp. 4
Exp. 1 Exp. 2 Exp. 3 Exp. 4
▪ CONTROL ▪ STRETCH
Figure 2 - Eff ects of Mechanical Stretch on hESC-CMs. (A) Changes in CM size. Areas of at least 200 cells 
per condition per experiment were measured; each experiment represents independent diff erentiation 
of hESCs into CMs. Two diff erent hESC lines were used: HUES9 and H9. Scale bar = 50 μm. ***p < 0.001 by 
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(+41.7% ± 6.8%, p < 0.05, n = 4), Figure 2D. We performed an additional analysis of 
orthogonal projections of the confocal images in order to determine the height or thick-
ness of the stretched and control cells. This analysis revealed that the height of stretched 
CMs was not changed compared with controls (10.78 ± 0.5 mm [stretched] versus 9.97 ± 
0.56 mm [controls], p > 0.1, n = 4; Figures 2E and S4D).
To assess CM apoptosis, an annexin V assay was used. Stretched CMs displayed a 4-fold 
(p < 0.01) increased staining of annexin V compared with control (Figures 3A and 3B). After 
48 hours of stretching we observed a significant 2-fold increase of lactate dehydrogenase 
(LDH), a marker of necrosis, in the supernatant from stretched cells (Figure 3C).
Cardiac hypertrophy is often accompanied by reactivation of fetal genes, i.e. genes that 
are active during fetal cardiac development and quiescent in adult heart19,20. We tested 
several such genes and showed that expression of atrial natriuretic peptide (ANP), B-type 
natiuretic peptide (BNP) but not TnT was altered by mechanical stretch in HUES9- and 
H9-derived CM (Figure 3D). In addition, 48 hours of stretch shifted the balance between 
α- and β-cardiac myosin heavy chains (MYH6 and MYH7, respectively) expression (Figure 
3D), which is a common response to the cardiac injury and hallmark of cardiac hypertro-
phy21,22.
Mechanical Stretch leads to Contractility dysfunction and Increases 
Stiffness of hESC-CM.
In order to determine whether stretch leads to the development of functional defects 
(e.g., contractile dysfunction), we assessed CM contraction force with atomic force mi-
croscopy (AFM) (Figure 4A). CMs subjected to mechanical stress showed a 1.6-fold slower 
beating frequency but not significantly affected beating force amplitude compared with 
control (Figures 4B and 4C). However, AFM observations of CM beating behavior have 
some limitations, since all the measurements were performed at room temperature. We 
also noticed changes in myofibril structure and sarcomere length after 48 hours of stretch 
Mann-Whitney U test. (B) Levels of TnT and NT-proBNP after 48hoursstretch of HUES9- and H9-derived CMs. 
*p < 0.05. (C) Levels of total ROS production in HUES9- and H9-derived CMs subjected to mechanical stress. 
Measured with CellROX Orange assay. For all graphs, each dot represents independent experiment and 
independent differentiation of hESCs into CMs. For all graphs, HUES9-CM is depicted in blue and H9-CM in 
orange. *p < 0.05, **p < 0.01. (D) Changes in CM volume derived from 3D reconstruction of live confocal 
images of control and stretched CMs; cell membranes were stained with wheat germ agglutinin fluorescein 
isothiocyanate (WGA-FITC) and nuclei with Hoechst. Images show an example of how the volume recon-
struction was performed. Volumes of at least 30 cells per condition per experiment were measured; each 
experiment represents independent differentiation of HUES9 into CM. Scale bar = 15 μm. *p < 0.05, **p < 
0.01, ***p < 0.001 by Mann-Whitney U test. (E) Changes in CM height derived from orthogonal projections 
of live confocal images of control and stretched CMs. Heights of at least 30 cells per condition per experi-
ment were measured; each experiment represents independent differentiation of HUES9 into CM. Scale bar 
= 50 μm. n.s., not significant by Mann-Whitney U test.
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(Figures 4D and 4E). The size of the sarcomeres was significantly increased after stretch 
(Figures 4D and 4E). We found that myofibrils in stretched hESC-CMs were distributed 
in parallel and appeared wider, whereas in control CMs myofibrils exhibited a more 
branched pattern and appeared more spatially separated (Figure 4D). In addition, the 












































































































Figure 3 - Effect of Mechanical Stretch on hESC-CM Viability. (A) Annexin V and Hoechst staining. Scale 
bar = 50 μm. (B) The total number of annexin V-positive cells as a percentage of total cell number shown 
as median of three independent experiments. (C) Level of LDH after 48hoursstretch of hESC-CMs, shown 
as a fold change between control and stretched samples obtained from four independent experiments. 
(D) qPCR analysis of the mRNA levels of ANP, BNP, TnT, and α- and β-myosin heavy chain (MHC) isoforms in 
HUES9- and H9-derived CMs after 48hoursstretch. Each dot represents the mean Ct (cycle threshold) values 
of triplicate measurements normalized against the values obtained for the 36b4 gene for the same sample. 
For all graphs, each dot represents an independent experiment and independent differentiation of hESCs 
into CMs. Median values for each condition are shown. *p < 0.05, **p < 0.01.



































































Figure 4 - Eff ect of Mechanical Stretch on HUES9-CM Contraction and Sarcomere Length. (A) AFM 
cantilever brought into contact with cardiac cell. The gray box shows typical beating force trajectory. Peaks 
represent contraction of the CM: height of the peaks characterizes force of the CM beat (nN) and beat-to-
beat distance represents beating rate (dT, seconds). (B) Eff ect of 48hoursmechanical stretch on CM beating 
rate, beats per minute (BPM). (C) Eff ect of 48 hours mechanical stretch on CM beating force. (D) Myofi brillar 
organization in control and stretched HUES9-CM. CMs were stained for troponin T and α-actinin with spe-
cifi c antibodies (red and green, respectively). Nuclei were stained with DAPI. Magnifi cation, 63× (oil). Scale 
bar = 10 μm. (E) Eff ect of mechanical stretch on CM sarcomere length measured as a distance between 
z-discs. (F) Young’s modulus of the HUES9-CMs subjected to mechanical stretch for 48 hr. The plots show 
the diff erence in elasticity for the untreated control cells and stretched CMs. All graphs show results of at 
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with untreated control cells, demonstrating that mechanical stretch leads to an increase 
of CM stiffness (Figure 4F). It is important to note that thinner cells potentially lead to 
inaccurate measurements of the elastic modulus. However, as described above, stretching 
did not result in flatter cells (Figures 2D and 2E). Moreover, we were able to image CMs 
by contact-mode atomic force scan using colloidal probe cantilever and show that there 
is no significant difference in CM height of control versus stretched CMs (6.1 ± 0.5 versus 
6.4 ± 1, p > 0.1, Figure S4). In addition, as was shown before, substrate contributions to 
the cell’s elastic modulus measurement can be neglected if the AFM tip indents less than 
10%-20% of the cell thickness24,25.
Effects of Mechanical Stretch on Gene Expression.
In order to determine genome-wide gene expression changes induced by mechanical 
stretch we performed RNA sequencing (RNA-seq) of seven independently derived pairs 
of control and stretched HUES9-CMs. Analysis of RNA-seq data identified 622 upregu-
lated genes and 1022 downregulated genes with a false discovery rate (FDR) below 
0.01 (Figure 5A, Tables S1 and S2, a Web interface for data search and visualization is 
available at http:// cardio.genomes.nl). Gene Ontology (GO) term enrichment analysis 
revealed that downregulated genes were mainly enriched in GOs such as cell cycle, chro-
mosome organization, DNA replication, and animal organ development (Table 1, Figure 
S4). Interestingly, animal organ development includes such GO terms as regulation of 
heart contraction, muscle structure development, and muscle system process (Figure S5). 
Upregulated GO terms were mainly enriched in regulation of apoptotic process, sterol 
biosynthetic process, and cytoskeleton organization (Table 1, Figure S5). In addition, KEGG 
(Kyoto Encyclopedia of Genes and Genomes) pathway analysis identified seven pathways 
that were upregulated (FDR < 0.02, Figure 5C, Table S4). Several of the downregulated 
pathways were enriched for a common set of regulatory (i.e., channels and mediators 
of Ca2+ concentration across the cell and contractility modulators) and structural genes 
(i.e., dystrophin, sarcoglycan alpha, members of integrin and collagen families) related to 
various cardiomyopathies (Table S4). KEGG pathway analysis also pointed toward signifi-
cant upregulation of apoptosis and of p53 signaling pathways, as well as upregulation of 
steroid biosynthesis (Figure 5B, Table S3). The KEGG pathway maps (obtained via KEGG 
Mapper v3.1 and available at http://cardio.genomes.nl) allow further detailed exploration 
of the networks and the effects of stretch on gene expression.
Figure 5 - Changes in CM Gene Expression upon Mechanical Stretch Identified by RNA Sequencing. 
(A) Mean (average) plots showing statistically significant (FDR < 0.01) differentially expressed genes in 
HUES9-CMs after 48hoursof stretch versus control. Average gene expression level is shown in counts per 
million (CPM). Position of SP6 and FSTL3 genes used in subsequent functional studies is indicated in red. 
See also Tables S1 and S2. (B) KEGG pathway analysis for upregulated genes in stretched CM. See also Table 
S3. (C) KEGG pathway analysis for downregulated genes in stretched CM. See also Table S4.
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dysregulation of SP6 and FStl3 expressions Play a Role in Stretched-
Induced Hypertrophy development in heSC-CM.
We chose to further explore two genes of particular interest. The first gene, specificity 
protein 6 (SP6), was the most upregulated gene and transcription factor identified in 
our RNA-seq dataset (Figure 5A). SP6 is a member of the SP family of transcription fac-
tors, which contains zinc finger DNA-binding domains in its structure and localizes in 
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Figure 6 - Knockdown of FSTL3 and SP6 in HUES9-CMs Decreases Level of Stretch-Induced Hyper-
trophy. (A) Immunostaining of HUES9-CMs expressing SCR-, FSTL3-, or SP6-specific shRNAs with specific 
antibodies against cardiac troponin T (green) and phalloidin. Images were taken on the control samples 
and samples subjected to mechanical stress for 48 hr. Scale bar = 50 μm. See also Figures S3 and S4. (B) 
Changes of cell size after stretch in CMs expressing SCR-, FSTL3-, or SP6-specific shRNAs were measured. 
Measurements were performed in at least four independent experiments. ***p < 0.001; n.s., not significant 
by Mann-Whitney U test. (C) HUES9-CMs expressing SCR-, Fstl3-, or SP6-specific shRNAs were stretched for 
48hoursand troponin T level in the growth media was measured. *p < 0.05; n.s., not significant. (D) HUES9-
CM expressing SCR-, Fstl3-, or SP6-specific shRNAs were stretched for 48 hours and levels of total ROS pro-
duction were measured. **p < 0.01; n.s., not significant.
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HUES9-CM would prevent the development of stretchinduced hypertrophy. The second 
gene, follistatin-like 3 (FSTL3), was chosen to validate already known molecular targets of 
cardiac hypertrophy development. Follistatin (FST) and follistatin-like genes (FSTL1, FSTL3) 
play an important role in heart failure development, and were linked to both disease 
severity and mechanisms underlying recovery28-32. Interestingly, all of these genes were 
dysregulated upon stretch (Tables S1 and S2), with FSTL3 being the most dysregulated 
among them at 2-fold upregulation upon stretch (Figure 5A). Changes in expression of 
FSTL3 and SP6 upon stretch were also validated on H9-CM (Figure S6A). HUES9-CMs 
were transduced by lentiviral vector expressing anti-FSTL3 short hairpin RNA (shRNA), 
anti-SP6 shRNA, and scrambled control (SCR) shRNA. qRT-PCR analysis confirmed that 
transduction resulted in more than 70% reduction in FSTL3 and SP6 gene expression 
compared with the SCR (Figure S6B) and SCR subjected to mechanical stretch (Figure 
S6C). hESC-CMs expressing SCR-, FSTL3-, and SP6-specific shRNAs were stretched for 48 
hours and assessed for cell size changes (Figure 6A). In CMs expressing SCR-shRNA, expo-
sure to 15% mechanical stretch led, as expected, to a significant increase of cell size area 
(Figure 6B), TnT release (Figure 6C), and ROS production (Figure 6D). Knockdown of FSTL3 
and SP6 in human CMs resulted in resilience to stretch-induced cardiac hypertrophy and 
resilience to oxidative stress (Figures 6B-6D).
dISCuSSIon
In the present study, we employ mechanical stretching of hESC-CMs as a human disease 
model for cardiac hypertrophy. We show dysregulation at the cellular, functional, and 
genomic levels upon stretching. All specific hypertrophic hallmarks, such as increase 
of cell size, elevated levels of stress biomarkers, and shift in fetal genes expression, are 
observed. In addition, we notice an increase in cellular stiffness and decreased contractil-
ity accompanied by changes of the sarcomeric structure. Intervention via knockdown of 
genes of interest resulted in resilience to the hypertrophic phenotype upon stretch.
Several proteins are involved in sensing and responding to stretch in the heart, the 
so-called mechanosensors33,34. Upon mechanical load, alterations in these proteins result 
in mechanical signaling leading to hypertrophy33,35. These changes can take place at vari-
ous sites in the CM, including the sarcomere, sarcolemma, and intercalated disc33,36. To 
determine the global gene expression changes involved in the hypertrophic response to 
mechanical stress, we used an RNA-seq approach. For instance, the ANKRD1 gene, which 
is 1.5-fold upregulated in our dataset (Table S1), is a transcription factor that interacts 
with the sarcomeric protein titin and plays a role in the myofibrillar stretchsensor system. 
Increased levels of this protein have been detected in heart tissue of patients suffering 
from ischemic cardiomyopathy and dilated cardiomyopathy37,38. It was also demonstrated 
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that ANKRD1 upregulation is associated with altered systolic/ diastolic function and that 
mutations in this gene result in a differential stretch-induced gene expression pattern37,39. 
FHL1 is another titin-binding protein that has been shown to be upregulated in mouse 
models in response to pressure-overloadinduced hypertrophy and in the hearts of human 
patients exhibiting hypertrophic40,41. This is in line with our RNA-seq data that show a 
significant 1.5-fold upregulation of FHL1 in stretched hESC-CMs (Table S1). Also, other 
members of the LIM domain family that have been implicated in mechanical strain signal-
ing, such as PDLIM3 and LDB3, were significantly dysregulated upon stretch (2-fold up and 
1.5-fold down, respectively). LDB3 and PDLIM3 are known to interact with the a-actinin 
rod domain within z-disc and ablation of these proteins in mice resulted in abnormal 
cardiac function and severe myopathy38,42.
Our AFM data showed that hESC-CMs subjected to mechanical stretch were significantly 
stiffer. Increased CM stiffness is one of the hallmarks of myocardial remodeling43,44. There 
are several factors that influence cardiac stiffness, such as changes in sarcomere length, 
myofibril density, shift in N2A to N2B titin’s isoforms expression, and titin phosphory-
lation43-45. Even though titin expression was not changed upon stretch, KEGG pathway 
analysis revealed downregulation of cGMP-PKG signaling pathway. This downregulation 
further contributes to the deficit of titin phosphorylation and overall increase of CM stiff-
ness46. Also, stiffness increases under oxidative stress conditions due to disulfide-bridge 
formation, which can occur in titin filaments47. We believe that changes in sarcomeric 
organization observed upon CM stretch could also contribute to the changes in cardiac 
stiffness. There is a significant dysregulation in the expression of MYOM2, MYPN, FHL1, 
SQSTM1, CRYAB, OBSCN, PBK, and MDM2. All these genes encode proteins, interact with 
titin, and affect myofibril formation34,47.
In addition to changes in myofibril architecture, regulation of cardiac muscle contraction 
was one of the significantly downregulated processes according to the GO term enrich-
ment analysis. Our RNA-seq data showed significant deregulation of ion homeostasis, 
one of the essential regulators of cardiac contraction48. We observed significant down-
regulation of Ca2+-channels, such as RYR2, CACNA1D, CACNG6, CACNA1H, and CACNB2 
(Table S2). We also found a downregulation of potassium (K+) and sodium (Na+) channels 
encoding genes such as SCN9A, SCN8A, ATP1A2, KCNQ1, HCN1, KCNN2, KCNAB2, and 
KCNH7 (Table S2). Multiple studies demonstrated that alterations in Ca2+ release and 
disturbance of K+ and Na+ ion channels cause abnormalities in CM beating behavior49-51. 
These observations are also in line with our AFM results showing that stretched CMs need 
more time to generate beats of the same force amplitude compared with control.
The GO term enrichment analysis of differentially expressed genes showed that me-
chanical stretch upregulates biological processes such as apoptosis, sterol biosynthesis, 
and cytoskeleton organization. This is in line with our phenotyping data, which also 
demonstrate that mechanical stretch causes increase of ROS production, necrosis, as well 
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as apoptosis in CMs, and could be responsible for cell loss. Similar findings have been 
reported for rat CM and human biopsy studies, in which cardiac hypertrophy develop-
ment was associated with induction of significant apoptotic and necrotic responses43,52-54.
As the heart begins to fail, disruption of its homeostasis leads to the release of stress-
related cytokines, proteins, or peptides, into the circulation. In our in vitro model system 
NT-pro-BNP and TnT are released in the supernatant upon stretching. Another well-known 
cardiac biomarker is GDF-15. It has been shown to be upregulated in patients with various 
forms of heart failure and is associated with an impaired prognosis55,56. Interestingly, GDF-
15 was among the top ten upregulated genes identified in our RNA-seq dataset. These 
findings suggest that our in vitro model combined with the RNA-seq approach can be 
used for identification and validation of circulating biomarkers involved in cardiac failure.
We used obtained RNA-seq data not only for studying potential candidates, such 
as SP6, the most induced transcription factor in the dataset, but also for validation of 
previously identified candidate genes such as FSTL3. This gene has been reported as an 
important player in cardiac remodeling. Expression of FSTL3 was shown to be elevated in 
tissue biopsies of patients with heart failure and levels correlated with a-skeletal actin and 
BNP, both markers of disease development28-30. As well as BNP, plasma levels of FSTL3 
were shown to be increased in heart failure patients and associated with the severity of 
the disease, suggesting its potential role as a circulating biomarker57. In addition to being 
secreted, FSTL3 can be found in both the nucleus and cytoplasm, which implies its in-
volvement in transcriptional regulation of cardiac remodeling28,29. Knockdown of FSTL3, as 
well as SP6, caused significant desensitization of CMs toward stretch-induced stress. This 
is in line with previously obtained in vivo and in vitro studies that show FSTL3 induction 
under myocardial stress and its negative effect on CM survival. A cardiac-specific FSTL3 
knockout mouse model showed significantly smaller infarct sizes and lower number of 
apoptotic myocytes after ischemia/reperfusion injury. Knockdown of FSTL3 in cultured rat 
CMs inhibited phenylephrine-induced cardiac hypertrophy29,30,32. Similarly, in our study, 
FSTL3 ablation in human CMs subjected to mechanical stretch led to the reduced level 
of cardiac hypertrophy and less cardiac damage assessed by level of TnT release and 
ROS production. Transcription factor SP6 has never been studied in relation to cardiac 
hypertrophy development. However, two other members of the SP family, SP1 and SP3, 
are both significantly overexpressed in hypertrophied and fetal murine hearts and are 
believed to be involved in cardiac hypertrophy development58.
Current advances in tissue engineering techniques made 3D cardiac tissue cultures 
feasible and potentially useful for pharmacological and clinical applications59-62. In addi-
tion, two-dimensional (2D) and 3D stem cell-derived CM cultures were used in a number 
of studies in order to address the immaturity of stem cell-derived CMs by employing a 
variety of biochemical and biophysical signals59-62. Furthermore, there are several studies 
that applied 3D tissue culturing for studying stretch- or phenylephrine-induced cardiac 
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hypertrophy63,64. We elected to use 2D CM cultures as a basis for our study for several 
reasons. While 3D tissues provide a more physiologically relevant structure, the major 
incentive for using this model is the requirement of non-CMs to be incorporated in 3D 
tissues for optimal function and tissue functionality65. This would impede the attribution 
of stretch-induced effects specifically to CM. Moreover, constructed 3D tissues are based 
on various compositions of extracellular matrix (ECM), which undergoes cell-mediated 
remodeling at all times. Consequently, changes in ECM characteristics might alter the 
strain on specific parts of a tissue, thereby making the tissue unstable and prone to break, 
and reproducibility is rendered difficult. 3D tissues also have different diffusion rates of 
soluble factors depending on the location of individual cells within the tissue, resulting in 
heterogeneous cell behavior and therefore matrix remodeling. Combined, these traits of 
3D tissues make characterization (of tissue as a whole) more complicated than with 2D 
cultures66.
To summarize, in the present study we show that mechanical stretching of hESC-CMs 
can serve as an in vitro disease model for studying human CM hypertrophy. This model 
broadens our understanding of the molecular mechanisms behind mechanotransduction 
and cardiac hypertrophy and can serve as a launch platform for development of pharma-
cological approaches as well as for discovering p
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Immunostaining, Cell Size and Sarcomere length determination
CM subjected to mechanical stretch and controls were fixed directly on Geltrex-coated 
silicone membranes of BioFlex six-well plates. After stretch CM were washed twice with 
ice-cold PBS and fixed in 4% paraformaldehyde (PFA) for 5 minutes on ice, permeabilized 
with ice-cold PBS + 0.3% Triton X100 for 5 minutes and then washed twice with PBS. 
Cells were incubated for 1 hour in blocking solution: 3% BSA (Serva), 2% goat serum 
(Sigma Aldrich), 0.1% Tween 80 (Sigma-Aldrich) in PBS. Primary antibodies were diluted in 
blocking solution and incubated with the cells for 1 hour at room temperature. All used 
primary and secondary antibodies are listed in Table S5. Coverslips were mounted using 
Vectashield mounting medium with DAPI (Vector Laboratories). 4 to 7 random pictures 
were taken with 20x magnification and 150-200 cells/per condition were analyzed in order 
to determine cell size. Image processing software, manual pipeline (CellProfiler, Broad 
Institute of MIT and Harvard in Cambridge) was used to determine the effect of stretch on 
cell size68. The error of the measurements was determined and did not exceed 2% (Figure 
S5). Sarcomere length was determined as a distance between z-bands on images taken 
with 63x magnification. Sarcomere length was analyzed using Fiji software69. All slides 
were imaged on a Leica AF-6000 microscope.
Quantitative Real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen), according to the manufactur-
ers’ instructions. Superscript III Reverse Transcription Kit (Life Technologies) was used for 
cDNA synthesis. Quantitative real-time PCR was performed on Roche LC480 (Roche) using 
SYBRGreen Master Mix (BioRad). Each sample was run in triplicate in a total volume of 
15 μL. Ribosomal protein lateral stalk subunit P0 (RPLP0 or 36B4) was used as a reference 
gene for normalization. Primer sequences are listed in Table S6.
Oxidative Stress Quantification
Total ROS production was quantified using CellROX Orange assay (Thermo Fisher Sci-
entific). The intensity of CellROX Orange fluorescence is proportional to the level of free 
radical oxidation. Control and stretched CM were loaded with 5 µM CellROX Orange in 
culture medium and stained in the dark for 60 minutes at 37°C. Stained cells were washed 
once with PBS, dissociate with TrypLE and suspended in PBS. Cells were centrifuged for 
5 minutes at 2000x g and suspended in 600 µl of PBS. 100 µl of cell suspension were 
transferred to a black 96 well plate (5 wells per condition) and analyzed immediately on a 
Synergy H1 microplate reader (Biotek) using 540/570 nm excitation/emission wavelength. 
For each condition the signal intensity was corrected to the number of cells as counted 




After 48 hours of stretch, cells were washed once with PBS and once with binding buffer 
(BD Bioscience), piece of the membrane was cut out and incubated in 150 μL of staining 
solution (used ratio: 5 μL of Annexin V-FITC (BD Bioscience) in 100 μL of binding buffer) in 
the dark for 15 minutes at room temperature. Cells were washed once with binding buffer, 
counterstained with Hoechst and fixed with 2% PFA in binding buffer before analysis.
shRnA-encoding lentiviral Particles Production
HEK 293T cells, grown at 37°C and 5% CO2 to 70% confluency in Dulbecco modified 
Eagle medium (DMEM, Thermo Fisher Scientific) supplemented with 10% fetal calf serum 
(FCS, Sigma Aldrich) were co-transfected with a constant amount of pCMV ∆8.91-transfer 
plasmid, VSV-G-packaging plasmid and pLKO.1-plasmid expressing short hairpin RNA 
(shRNA) of interest. Fugene HD (Promega) transfection agent was used to improve 
transfection efficiency. After 24 hours media were replaced with fresh CDM3 media. After 
24 hours CDM3 medium containing viral particles was harvested and filtered with 0.45 
nm Nalgene filter to prevent HEK293T cells to be transferred to the solution. Clean viral 
supernatant was aliquoted and frozen at −80°C. pLKO.1 is a replication-incompetent 
lentiviral vector used for expression of shRNAs in CM. pLKO.1.shSP6, pLKO.1.shFSTL3, 
pLKO.1.shSCR (scrambled control) were purchased from Sigma MISSION RNAi. See shRNA 
probe sequences in Table S7.
Stable transduction heSC-derived CM with shRnA-encoding lentivirus
hECS-CM were plated on BioFlex six-well plates to have approximately 80% confluence 
at the time of transduction. For transduction, 1 ml of viral supernatant and 1 ml of fresh 
CDM3 media supplemented with 4 µg of polybrene (Sigma Aldrich) were added to the 
cells and incubated at 37°C for 18 hours. Next day viral particles were washed and 3 ml 
of fresh CDM3 media was added to the cells. Medium was changed every other day. On 
day 3 after transduction medium was aspirated and 3 ml of CDM3 medium supplemented 
with 4 µg/ml puromycin (Thermo Fisher Scientific) was placed into each well. Medium 
supplemented with puromycin was changed every other day and after 4 days of puromy-
cin selection, cells were used for the downstream assays.
levels of tnt, nt-proBnP, ldH in Cell Culture Media
Levels of damage-related biomarkers Troponin T (TnT), lactate dehydrogenase (LDH) and 
the N-terminal fragment of the prohormone of brain natriuretic peptide (NT-proBNP) were 
analyzed in the culturing media. LDH levels have been determined using an UV assay LDH 
kit (11822837, Roche Diagnostics). TnT and NT-proBNP levels were analyzed using electro-
chemiluminescence immunoassay kits (0509277 and 04842464 respectively, Roche Diag-
nostics). For every independent experiment, measurements were done at least in duplicate.




























































Supplementary Figure S1 -  Eff ects of Mechanical Stretch Duration on HUES9-CM. Related to Figure 2. 
(A) Equiaxial strain application on hESC-derived CM. (B) Levels of TnT, NT-proBNP measured in CM’s media 
after mechanical stretch at 7hrs, 24hrs and 48-hour time-points. (C) qPCR analysis of the mRNA levels of TnT 
and BNP in HUES9-derived CM after 7, 24 and 48 hours of stretch. Each dot represents the mean Ct values 
of triplicate measurements normalized against the values obtained for 36b4 gene for the same sample. For 
all graphs each dot represents independent experiment and independent diff erentiation of HUES9-hESCs 
















































Supplementary Figure S2 - Effects of 5 % Mechanical Stretch on HUES9-derived CM. (A) Immunostain-
ing of HUES9-CM with phalloidin. Nuclei stained with DAPI. Images were taken on the control samples and 
samples subjected to 5% stretch for 48 hrs. Scale bar = 50 μm. (B) Cell size changes of HUES9-CM subjected 
to 5% stretch for 48 hrs. At least 80 cells were analyzed per condition. n.s., not significant; by Mann-Whitney-
U-test. (C) Level of troponin T, measured in CM’s media after 5% mechanical stretch. (D) qPCR analysis of 
the mRNA levels of ANP, BNP, TnT, α- and β-MHC in CM after 48 hours of 5% stretch. Each dot represents the 
mean Ct values of triplicate measurements normalized against the values obtained for 36b4 gene for the 
same sample. For all graphs each dot represents independent experiment and independent differentiation 
of hESCs into CM.
A B
Supplementary Figure S3 - Accuracy of CM Size Measurement. Related to Figure 2. (A) Determination 
of the error of the CM size measurements. Sizes of at least six cells from the same image were repeatedly 
measured for at least 9 times, standard deviation (SD) of the measurements were used to calculate error 
mean. Results are based on 2 independent experiments, 2 independent HUES9-CM cultures. (B) Example of 
how the measurements were performed.


















Supplementary Figure S4 - Effects of 15 % Mechanical Stretch on HUES9-CM height via Confocal Mi-
croscopy and Atomic Force Microscopy (AFM). Related to Figures 2 and 4. AFM image of control (A) and 
stretched (B) hESC-CM in contact mode overlaid with AFM height image. Examples of height measure-
ments along the lines displayed in far-right panels for control and stretched CM. (C) Changes in CM height 
derived from AFM images of control and stretched CMs. Measurements are based on 3 independent experi-
ments. (D) Examples of orthogonal projections derived from the confocal images of control and stretched 















































































































































































































































































































































































































































































































Supplementary Figure S5 - Gene Ontology Analysis of Genes Up- and Down-regulated upon Stretch. 
Related to Table 1. The analysis was performed using GOrilla and visualized with REVIGO, which performed 
removal of redundant GO terms and generated tree maps of the functional annotations associated with the 
up-regulated (A) and the down-regulated genes (B).
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Supplementary Figure S6 - Validation of FSTL3 and SP6 Knockdowns. Related to Figure 6. (A) Valida-
tion of FSTL3 and SP6 gene expression in H9-CM. FSTL3 and SP6 are significantly up-regulated in H9-CM 
upon 48 hours stretch. (B) mRNA expression levels of FSTL3 and SP6 in the shRNA transduced HUES9-CM. 
Expression levels are relative to untreated scramble (SCR) control. (C) mRNA expression levels of FSTL3 and 
SP6 in the shRNA transduced HUES9-CM subjected to mechanical stretch. Expression levels are relative to 
stretched scramble control (Ctrl). For all graphs each dot represents the mean Ct values of triplicate mea-
surements normalized against the values obtained for 36b4 gene for the same sample. Measurements are 




Table S1 - List of up-regulated genes upon stretch identified by the RNA-seq analysis. The table rep-
resents fold change of gene expression, significance (p-value and FDR) and gene description. Available in 
online version.
Table S2 - List of down-regulated genes upon stretch identified by the RNA-seq analysis. The table 
represents fold change of gene expression, significance (p-value and FDR) and gene description. Available 
in online version.







FDR matching proteins in analyzed network
100 Steroid biosynthesis 9 4.58e-07 CYP2R1, DHCR24, DHCR7, EBP, FDFT1, 




7 0.000184 ACAT2, FDPS, HMGCR, HMGCS1, ICMT, IDI1, 
MVD
4115 p53 signaling 
pathway
11 0.000247 BAX, CDKN1A, FAS, GADD45A, MDM2, 





11 0.000512 BMS1, EIF6, GTPBP4, HEATR1, LSG1, 
MPHOSPH10, NOL6, RPP25, RPP38, TCOF1, 
UTP6
1100 Metabolic pathways 56 0.00605 ACAT2, ACLY, ACOX3, ACSS2, AGPAT9, 
AKR1C3, ALAD, ALG8, ARG2, ATP6V0E1, 
ATP6V1D, CHPF2, CKB, COASY, CYP2R1, 
DHCR24, DHCR7, EBP, ENO2, ENO3, ENPP1, 
FASN, FDFT1, FDPS, G6PD, GCLC, HMGCR, 
HMGCS1, HSD17B7, IDI1, INPP1, INPP5K, 
ITPKB, LIPG, LPIN1, ME1, MMAB, MSMO1, 
MVD, NSDHL, OCRL, P4HA1, P4HA2, PC, 
PNPLA3, POLG, POLR1C, RPN2, RRM2B, 
SHMT2, SMPD2, SQLE, ST3GAL2, ST6GAL1, 
SYNJ2, TKT
4210 Apoptosis 10 0.00697 AIFM1, BAX, BCL2L1, CAPN2, FAS, RIPK1, 
TNFRSF10A, TNFRSF10B, TNFRSF10D, 
TNFRSF1A
4141 Protein processing 
in endoplasmic 
reticulum
14 0.0103 ATF4, BAX, CAPN2, CRYAB, DDIT3, DNAJA1, 
BXO2, HSP90AA1, HSPH1, NPLOC4, RPN2, 
UBE2J2, UBQLN4, UFD1L
Modeling hypertrophy in human cardiomyocytes
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FDR matching proteins in analyzed network
4974 Protein digestion 
and absorption
19 4.06e-06 ATP1A3, ATP1B2, COL14A1, COL18A1, COL1A1, 
COL22A1, COL27A1, COL2A1, COL3A1, COL4A2, 
COL4A5, COL4A6, COL6A1, COL6A2, COL6A3, 
COL7A1, KCNQ1, SLC16A10, SLC8A1
4512 ECM-receptor 
interaction
18 1.44e-05 AGRN, COL1A1, COL27A1, COL2A1, COL3A1, 
COL4A2, COL4A5, COL4A6, COL6A1, COL6A2, 
COL6A3, HMMR, ITGA10, ITGA11, ITGA8, LAMA4, 
LAMA5, LAMC1
3030 DNA replication 10 0.000387 LIG1, MCM2, MCM4, MCM5, MCM6, POLE2, RFC3, 
RNASEH2A, RNASEH2B, RPA1
4110 Cell cycle 18 0.00098 BUB1, BUB1B, CCNA2, CCNB1, CCNB2, CDC20, 
CDC45, CDC6, ESPL1, MAD2L1, MCM2, MCM4, 




20 0.00098 ADCY3, ADCY7, ATP1A3, ATP1B2, CACNA1D, 
CACNB2, CACNG6, CAMK2B, CREB3L4, KCNQ1, 
MYH6, PLCB2, PLN, PPP1CC, PPP1R1A, PPP2R2B, 
PPP2R3A, RPS6KA5, RYR2, SLC8A1
5414 Dilated 
cardiomyopathy
15 0.00098 ADCY3, ADCY7, CACNA1D, CACNB2, CACNG6, 
DMD, ITGA10, ITGA11, ITGA8, MYH6, PLN, RYR2, 
SGCA, SLC8A1, TGFB2
4022 cGMP-PKG signaling 
pathway
20 0.00295 ADCY3, ADCY7, ATP1A3, ATP1B2, CACNA1D, 
CREB3L4, GUCY1A2, MEF2A, MEF2C, NFATC1, 
NFATC2, PDE3A, PDE3B, PDE5A, PLCB2, PLN, 




12 0.00658 CACNA1D, CACNB2, CACNG6, CTNNA3, DMD, 
GJA1, ITGA10, ITGA11, ITGA8, RYR2, SGCA, 
SLC8A1
4510 Focal adhesion 22 0.0104 COL1A1, COL27A1, COL2A1, COL3A1, COL4A2, 
COL4A5, COL4A6, COL6A1, COL6A2, COL6A3, 
DOCK1, ITGA10, ITGA11, ITGA8, KDR, LAMA4, 
LAMA5, LAMC1, PDGFD, PDGFRB, PPP1CC, TLN2
4921 Oxytocin signaling 
pathway
18 0.0116 ADCY3, ADCY7, CACNA1D, CACNB2, CACNG6, 
CAMK2B, CAMKK2, EEF2K, GUCY1A2, KCNJ5, 
MAP2K5, MEF2C, NFATC1, NFATC2, PLCB2, 
PPP1CC, PPP3R1, RYR2
4114 Oocyte meiosis 14 0.0123 ADCY3, ADCY7, BUB1, CAMK2B, CCNB1, CCNB2, 
CDC20, ESPL1, MAD2L1, PLK1, PPP1CC, PPP3R1, 
PTTG1, SGOL1
5146 Amoebiasis 14 0.0123 COL1A1, COL27A1, COL2A1, COL3A1, COL4A2, 
COL4A5, COL4A6, GNAL, LAMA4, LAMA5, 




12 0.0123 CACNA1D, CACNB2, CACNG6, DMD, ITGA10, 








Table S5 -  List of primary and secondary antibodies used in the study. IF: immunofluorescence.
Primary AB Host Source Application
Anti-Troponin T Rabbit Abcam IF (1:100)
Anti-α-actinin Mouse Sigma Aldrich IF (1:100)
Secondary AB Host Source Application
Anti-rabbit IgG-FITC Goat Southern Biotech IF (1:200)
Anti-rabbit IgG-TRITC Goat Southern Biotech IF (1:100)
Anti-mouse IgG-FITC Goat Southern Biotech IF (1:200)
Anti-mouse IgG-TRITC Goat Southern Biotech IF (1:100)


















Table S7 - List of shRNA probes used in the study. All additional information about probes and pLKO1 
plasmid can be found on manufacturer website.
Gene 
name
Clone ID Sequence Region
Sp6 NM_199262.2-
1229s21c1
5’-CCGGAGTCTGCAGCCGCGTCTTCATCTCGAGATGAAGACGCG-
GCTGCAGACTTTTTTTG-‘3
CDS
Fstl3 NM_005860.2-309s21c1 5’-CCGGTGCCTTCCCTGCAAAGATTCGCTCGAGCGAATCTTTG-
CAGGGAAGGCATTTTTG-‘3
CDS


PARt II

